重组艾滋病毒-2 gp36(390-702)/HIV-2 gp-36 (390-702 a.a.)_详细资料

产品信息 重组艾滋病毒-2 gp36(390-702)/HIV-2 gp-36 (390-702 a.a.) 产品编号：HIV-139 产品规格：100μg/500μg/1mg Catalogue Number HIV-139 Introduction HIV-1 and HIV-2 appear to package their RNA differently. HIV-1 binds to any appropriate RNA whereas HIV-2 preferentially binds to mRNA which creates the Gag protein itself. This means that HIV-1 is better able to mutate. HIV-2 is transmitted in the same ways as HIV-1: Through exposure to bodily fluids such as blood, semen, tears and vaginal fluids. Immunodeficiency develops more slowly with HIV-2. HIV-2 is less infectious in the early stages of the virus than with HIV-1. The infectiousness of HIV-2 increases as the virus progresses. Major differences include reduced pathogenicity of HIV-2 relative to HIV-1, enhanced immune control of HIV-2 infection and often some degree of CD4-independence. Despite considerable sequence and phenotypic differences between HIV-1 and 2 envelopes, structurally they are quite similar. Both membrane-anchored proteins eventually form the 6-helix bundles from the N-terminal and C-terminal regions of the ectodomain, which is common to many viral and cellular fusion proteins and which seems to drive fusion. HIV-1 gp41 helical regions can form more stable 6-helix bundles than HIV-2 gp41 helical regions however HIV-2 fusion occurs at a lower threshold temperature (25°C), does not require Ca2+ in the medium, is insensitive to treatment of target cells with cytochalasin B, and is not affected by target membrane glycosphingolipid composition. Description HIV-2 gp36 34 kDa recombinant- contains the sequence of HIV-2 envelope immunodominant regions gp36, amino acids 390-702. The protein is fused to beta-galactosidase (114 kDa) at N-terminus. Source Escherichia Coli. Physical Appearance Sterile filtered colorless clear solution. Formulation 0.01M Na2CO3, 0.01M Na3EDTA, 0.014 M?-mercaptoethanol, 0.02% Sarcosyl. Purity Greater than 95.0% as determined by HPLC analysis and SDS-PAGE. Stability Protein should be stored at 4°C. Refrigerate Upon arrival. DO NOT FREEZE. Amino Acid Sequence EQTMVQDDPSTCRGEFLYCNMTWFLNWIENKTHRNYAPCH IKQIINTWHKVGRNVYLPPREGELSCNSTVTSIIANIDWQ NNNQTNITFSAEVAELYRLELGDYKLVEITPIGFAPTKEK RYSSAHGRHTRGVFVLGFLGFLATAGSAMGAASLTVSAQS RTLLAGIVQQQQQLLDVVKRQQELLRLTVWGTKNLQARVT AIEKYLQDQARLNSWGCAFRQVCHTTVPWVNDSLAPDWDN MTWQEWEKQVRYLEANISKSLEQAQIQQEKNMYELQKLNS WDIFGNWFDLTSWVKYIQYGVLIIVAVIALRIVIYVVQML SRLRKGYRPVFSSPPGYIQQIHIHKDRGQPANEETEEDGG SNGGDRYWPWPIAYIHFLIRQLIRLLTRLYSICSQAC. Specificity Immunoreactive with all sera of HIV-2 infected individuals. Applications HIV-2 gp-36 antigen in ELISA and Western blots, excellent antigen for early detection of HIV seroconvertors with minimal specificity problems. Usage ProSpec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

您可能感兴趣的产品

Catalogue Number	HIV-139
Introduction	HIV-1 and HIV-2 appear to package their RNA differently. HIV-1 binds to any appropriate RNA whereas HIV-2 preferentially binds to mRNA which creates the Gag protein itself. This means that HIV-1 is better able to mutate. HIV-2 is transmitted in the same ways as HIV-1: Through exposure to bodily fluids such as blood, semen, tears and vaginal fluids. Immunodeficiency develops more slowly with HIV-2. HIV-2 is less infectious in the early stages of the virus than with HIV-1. The infectiousness of HIV-2 increases as the virus progresses. Major differences include reduced pathogenicity of HIV-2 relative to HIV-1, enhanced immune control of HIV-2 infection and often some degree of CD4-independence. Despite considerable sequence and phenotypic differences between HIV-1 and 2 envelopes, structurally they are quite similar. Both membrane-anchored proteins eventually form the 6-helix bundles from the N-terminal and C-terminal regions of the ectodomain, which is common to many viral and cellular fusion proteins and which seems to drive fusion. HIV-1 gp41 helical regions can form more stable 6-helix bundles than HIV-2 gp41 helical regions however HIV-2 fusion occurs at a lower threshold temperature (25°C), does not require Ca2+ in the medium, is insensitive to treatment of target cells with cytochalasin B, and is not affected by target membrane glycosphingolipid composition.
Description	HIV-2 gp36 34 kDa recombinant- contains the sequence of HIV-2 envelope immunodominant regions gp36, amino acids 390-702. The protein is fused to beta-galactosidase (114 kDa) at N-terminus.
Source	Escherichia Coli.
Physical Appearance	Sterile filtered colorless clear solution.
Formulation	0.01M Na2CO3, 0.01M Na3EDTA, 0.014 M?-mercaptoethanol, 0.02% Sarcosyl.
Purity	Greater than 95.0% as determined by HPLC analysis and SDS-PAGE.
Stability	Protein should be stored at 4°C. Refrigerate Upon arrival. DO NOT FREEZE.
Amino Acid Sequence	EQTMVQDDPSTCRGEFLYCNMTWFLNWIENKTHRNYAPCH IKQIINTWHKVGRNVYLPPREGELSCNSTVTSIIANIDWQ NNNQTNITFSAEVAELYRLELGDYKLVEITPIGFAPTKEK RYSSAHGRHTRGVFVLGFLGFLATAGSAMGAASLTVSAQS RTLLAGIVQQQQQLLDVVKRQQELLRLTVWGTKNLQARVT AIEKYLQDQARLNSWGCAFRQVCHTTVPWVNDSLAPDWDN MTWQEWEKQVRYLEANISKSLEQAQIQQEKNMYELQKLNS WDIFGNWFDLTSWVKYIQYGVLIIVAVIALRIVIYVVQML SRLRKGYRPVFSSPPGYIQQIHIHKDRGQPANEETEEDGG SNGGDRYWPWPIAYIHFLIRQLIRLLTRLYSICSQAC.
Specificity	Immunoreactive with all sera of HIV-2 infected individuals.
Applications	HIV-2 gp-36 antigen in ELISA and Western blots, excellent antigen for early detection of HIV seroconvertors with minimal specificity problems.
Usage	ProSpec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.